Skip to content
SCOUT CLINICAL | CASE STUDY

Participant Access and Retention in Metastatic Colorectal Cancer Trials

Supporting participants managing advanced disease and frequent visits across complex oncology protocols

Background

Metastatic colorectal cancer trials involve advanced disease burden, gastrointestinal symptoms, and frequent visits for treatment and assessment.

Travel demands and physical strain increase the risk of missed visits and early withdrawal without consistent coordination.

Scope

Scout supported participant engagement across metastatic colorectal cancer trials involving frequent visits and complex treatment schedules.

Support included coordination of travel, lodging, and reimbursements across all study visits, enabling access to specialized sites while maintaining alignment with protocol requirements over time.

Challenges

  • Advanced disease burden impacting stamina
  • GI symptoms affecting travel tolerance
  • Frequent visits for treatment and assessment
  • Long-distance travel to specialized sites
  • Risk of missed visits and early withdrawal

Scout's Approach

Travel coordination: Arranged and prepaid transportation and lodging.

Financial barrier reduction: Removed upfront costs through direct management.

Visit logistics management: Coordinated travel and accommodations across visits.

Caregiver coordination: Facilitated approved caregiver involvement.

Participant planning: Aligned logistics with site schedules. 

Specialized Solutions

Support was structured to address both logistical and financial barriers, with travel and reimbursement coordination handled in advance and repeated consistently across visits. Planning accounted for fluctuating symptoms and reduced stamina, allowing participants to continue participation across demanding protocols.

Ongoing coordination reduced missed visits and administrative burden for sites while maintaining continuity for participants throughout the study.

Across Scout-supported oncology studies, retention reached 82.3%, representing a +13.9 percentage point improvement over non-Scout sites, with a 44% reduction in participant discontinuations and participants 21% more likely to complete their studies.